Clinical Trials
`
`Diseases
`
`Biomarkers
`
`Drugs
`
`Pathways
`
`Biomarkers /
`
`KIT Mutation
`
`Back to Biomarkers List
`
`Overview
`
`Associated Genetic
`
`Gene Location [ 1 ]
`
`4q12
`
`Pathway
`
`Gene
`
`Receptor tyrosine kinase/growth factor signaling
`
`KIT
`
`KIT Mutation is present in 2.41% of AACR GENIE cases, with gastrointestinal stromal tumor, lung adenocarcinoma, colon
`
`adenocarcinoma, endometrial endometrioid adenocarcinoma, and melanoma having the greatest prevalence [ 4 ].
`
`Top Disease Cases with KIT Mutation
`
`Biomarkers
`
`KIT
`
`Associated Diseases
`
`Cancer
`
`Myelodysplastic Syndromes
`
`Aggressive Systemic Mastocytosis
`
`Non-Small Cell Lung Carcinoma
`
`Soft Tissue Sarcoma
`
`Small Cell Lung Carcinoma
`
`Malignant Germ Cell Tumor
`
`Systemic Mastocytosis with an Associated
`
`Prostate Carcinoma
`
`Colorectal Carcinoma
`
`Nasopharyngeal Carcinoma
`
`Secondary Acute Myeloid Leukemia
`
`Malignant Laryngeal Neoplasm
`
`Oropharyngeal Carcinoma
`
`Acute Myeloid Leukemia
`
`Malignant Solid Tumor
`
`Thymic Carcinoma
`
`Malignant Salivary Gland Neoplasm
`
`Ovarian Carcinoma
`
`Bladder Carcinoma
`
`Show More...
`
`Associated Pathways
`
`Receptor tyrosine kinase/growth factor
`
`Clinical Trials
`
`View Clinical Trials for KIT Mutation
`
`KIT Mutation serves as an inclusion eligibility criterion in 71 clinical trials, of which 49 are open and 22 are closed. Of the
`
`trials that contain KIT Mutation as an inclusion criterion, 1 is early phase 1 (0 open), 16 are phase 1 (10 open), 8 are phase
`
`1/phase 2 (6 open), 35 are phase 2 (26 open), 2 are phase 2/phase 3 (2 open), 8 are phase 3 (5 open), and 1 is no phase
`
`specified (0 open).
`
`Trials with KIT Mutation in the inclusion eligibility criteria most commonly target acute myeloid leukemia, malignant solid
`
`tumor, gastrointestinal stromal tumor, melanoma, and non-small cell lung carcinoma [ 5 ].
`
`Trials Investigating KIT Mutation by Disease and Recruiting Status
`
`Fludarabine, cyclophosphamide, allogeneic hematopoietic stem cell transplantation, cytarabine, and imatinib are the most
`
`frequent therapies in trials with KIT Mutation as an inclusion criteria [ 5 ].
`
`Rigel Exhibit 1054
`Page 1 of 12
`
`

`

`Drugs Being Investigated in KIT Mutation Trials by Recruiting Status
`
`Significance of KIT Mutation in Diseases
`
`Acute Myeloid Leukemia
`
`-
`
`KIT is altered in 2.0% of acute myeloid leukemia patients with KIT Mutation present in 1.96% of all acute
`
`myeloid leukemia patients [ 4 ].
`
`KIT Mutation is an inclusion criterion in 31 clinical trials for acute myeloid leukemia, of which 19 are open and
`
`12 are closed. Of the trials that contain KIT Mutation and acute myeloid leukemia as inclusion criteria, 10 are
`
`phase 1 (5 open), 5 are phase 1/phase 2 (4 open), 10 are phase 2 (6 open), 2 are phase 2/phase 3 (2 open), 3
`
`are phase 3 (2 open), and 1 is no phase specified (0 open) [ 5 ].
`
`Myelodysplastic Syndromes
`
`-
`
`KIT is altered in 0.89% of myelodysplastic syndromes patients with KIT Mutation present in 0.89% of all
`
`myelodysplastic syndromes patients [ 4 ].
`
`KIT Mutation is an inclusion criterion in 20 clinical trials for myelodysplastic syndromes, of which 11 are open
`
`and 9 are closed. Of the trials that contain KIT Mutation and myelodysplastic syndromes as inclusion criteria, 10
`
`are phase 1 (5 open), 1 is phase 1/phase 2 (1 open), 7 are phase 2 (4 open), 1 is phase 3 (1 open), and 1 is no
`
`phase specified (0 open) [ 5 ].
`
`Gastrointestinal Stromal Tumor
`
`-
`
`KIT is altered in 71.19% of gastrointestinal stromal tumor patients with KIT Mutation present in 68.75% of all
`
`gastrointestinal stromal tumor patients [ 4 ].
`
`KIT Mutation is an inclusion criterion in 14 clinical trials for gastrointestinal stromal tumor, of which 13 are open
`
`and 1 is closed. Of the trials that contain KIT Mutation and gastrointestinal stromal tumor as inclusion criteria, 3
`
`are phase 1 (3 open), 1 is phase 1/phase 2 (1 open), 6 are phase 2 (6 open), and 4 are phase 3 (3 open) [ 5 ].
`
`Acute Lymphoblastic Leukemia
`
`-
`
`KIT Mutation is an inclusion criterion in 14 clinical trials for acute lymphoblastic leukemia, of which 8 are open
`
`and 6 are closed. Of the trials that contain KIT Mutation and acute lymphoblastic leukemia as inclusion criteria,
`
`6 are phase 1 (3 open), 1 is phase 1/phase 2 (1 open), 5 are phase 2 (3 open), 1 is phase 3 (1 open), and 1 is
`
`no phase specified (0 open) [ 5 ].
`
`Melanoma
`
`-
`
`KIT is altered in 6.55% of melanoma patients with KIT Mutation present in 5.89% of all melanoma patients [ 4 ].
`
`KIT Mutation is an inclusion criterion in 13 clinical trials for melanoma, of which 7 are open and 6 are closed. Of
`
`the trials that contain KIT Mutation and melanoma as inclusion criteria, 3 are phase 1 (2 open), 2 are phase
`
`1/phase 2 (1 open), 7 are phase 2 (4 open), and 1 is phase 3 (0 open) [ 5 ].
`
`Malignant Solid Tumor
`
`-
`
`KIT is altered in 3.15% of malignant solid tumor patients with KIT Mutation present in 2.63% of all malignant
`
`solid tumor patients [ 4 ].
`
`KIT Mutation is an inclusion criterion in 13 clinical trials for malignant solid tumor, of which 11 are open and 2
`
`are closed. Of the trials that contain KIT Mutation and malignant solid tumor as inclusion criteria, 5 are phase 1
`
`(4 open), 1 is phase 1/phase 2 (1 open), and 7 are phase 2 (6 open) [ 5 ].
`
`Rigel Exhibit 1054
`Page 2 of 12
`
`

`

`Chronic Myeloid Leukemia
`
`-
`
`KIT is altered in 0.85% of chronic myeloid leukemia patients with KIT Mutation present in 0.85% of all chronic
`
`myeloid leukemia patients [ 4 ].
`
`KIT Mutation is an inclusion criterion in 11 clinical trials for chronic myeloid leukemia, of which 7 are open and 4
`
`are closed. Of the trials that contain KIT Mutation and chronic myeloid leukemia as inclusion criteria, 5 are
`
`phase 1 (3 open), 2 are phase 1/phase 2 (2 open), 3 are phase 2 (2 open), and 1 is no phase specified (0
`
`open) [ 5 ].
`
`Multiple Myeloma
`
`KIT is altered in 0.4% of multiple myeloma patients with KIT Mutation present in 0.4% of all multiple myeloma
`
`patients [ 4 ].
`
`KIT Mutation is an inclusion criterion in 9 clinical trials for multiple myeloma, of which 6 are open and 3 are
`
`closed. Of the trials that contain KIT Mutation and multiple myeloma as inclusion criteria, 5 are phase 1 (3
`
`open), 3 are phase 2 (3 open), and 1 is no phase specified (0 open) [ 5 ].
`
`Chronic Myelomonocytic Leukemia
`
`KIT is altered in 2.54% of chronic myelomonocytic leukemia patients with KIT Mutation present in 2.54% of all
`
`chronic myelomonocytic leukemia patients [ 4 ].
`
`KIT Mutation is an inclusion criterion in 7 clinical trials for chronic myelomonocytic leukemia, of which 5 are
`
`open and 2 are closed. Of the trials that contain KIT Mutation and chronic myelomonocytic leukemia as
`
`inclusion criteria, 4 are phase 1 (3 open), 1 is phase 1/phase 2 (1 open), and 2 are phase 2 (1 open) [ 5 ].
`
`Non-Small Cell Lung Carcinoma
`
`-
`
`-
`
`-
`
`KIT is altered in 2.09% of non-small cell lung carcinoma patients with KIT Mutation present in 1.76% of all non-
`
`small cell lung carcinoma patients [ 4 ].
`
`KIT Mutation is an inclusion criterion in 7 clinical trials for non-small cell lung carcinoma, of which 6 are open
`
`and 1 is closed. Of the trials that contain KIT Mutation and non-small cell lung carcinoma as inclusion criteria, 3
`
`are phase 1 (2 open) and 4 are phase 2 (4 open) [ 5 ].
`
`Hodgkin Lymphoma
`
`KIT Mutation is an inclusion criterion in 7 clinical trials for hodgkin lymphoma, of which 3 are open and 4 are
`
`closed. Of the trials that contain KIT Mutation and hodgkin lymphoma as inclusion criteria, 5 are phase 1 (2
`
`open), 1 is phase 2 (1 open), and 1 is no phase specified (0 open) [ 5 ].
`
`Non-Hodgkin Lymphoma
`
`-
`
`-
`
`KIT is altered in 1.3% of non-hodgkin lymphoma patients with KIT Mutation present in 1.17% of all non-hodgkin
`
`lymphoma patients [ 4 ].
`
`KIT Mutation is an inclusion criterion in 6 clinical trials for non-hodgkin lymphoma, of which 3 are open and 3
`
`are closed. Of the trials that contain KIT Mutation and non-hodgkin lymphoma as inclusion criteria, 6 are phase
`
`1 (3 open) [ 5 ].
`
`Acute Biphenotypic Leukemia
`
`-
`
`KIT Mutation is an inclusion criterion in 6 clinical trials for acute biphenotypic leukemia, of which 2 are open and
`
`4 are closed. Of the trials that contain KIT Mutation and acute biphenotypic leukemia as inclusion criteria, 3 are
`
`phase 1 (1 open), 2 are phase 2 (1 open), and 1 is no phase specified (0 open) [ 5 ].
`
`Chronic Lymphocytic Leukemia
`
`-
`
`KIT Mutation is an inclusion criterion in 5 clinical trials for chronic lymphocytic leukemia, of which 3 are open
`
`and 2 are closed. Of the trials that contain KIT Mutation and chronic lymphocytic leukemia as inclusion criteria,
`
`4 are phase 1 (2 open) and 1 is phase 2 (1 open) [ 5 ].
`
`Myeloproliferative Neoplasm
`
`-
`
`KIT is altered in 0.59% of myeloproliferative neoplasm patients with KIT Mutation present in 0.59% of all
`
`myeloproliferative neoplasm patients [ 4 ].
`
`KIT Mutation is an inclusion criterion in 4 clinical trials for myeloproliferative neoplasm, of which 3 are open and
`
`1 is closed. Of the trials that contain KIT Mutation and myeloproliferative neoplasm as inclusion criteria, 1 is
`
`phase 1 (1 open), 2 are phase 2 (2 open), and 1 is no phase specified (0 open) [ 5 ].
`
`Myelodysplastic/Myeloproliferative Neoplasm
`
`-
`
`KIT is altered in 2.7% of myelodysplastic/myeloproliferative neoplasm patients with KIT Mutation present in
`
`2.7% of all myelodysplastic/myeloproliferative neoplasm patients [ 4 ].
`
`KIT Mutation is an inclusion criterion in 3 clinical trials for myelodysplastic/myeloproliferative neoplasm, of which
`
`2 are open and 1 is closed. Of the trials that contain KIT Mutation and myelodysplastic/myeloproliferative
`
`neoplasm as inclusion criteria, 1 is phase 1 (1 open) and 2 are phase 2 (1 open) [ 5 ].
`
`Acute Leukemia
`
`-
`
`KIT is altered in 1.95% of acute leukemia patients with KIT Mutation present in 1.91% of all acute leukemia
`
`patients [ 4 ].
`
`Rigel Exhibit 1054
`Page 3 of 12
`
`

`

`KIT Mutation is an inclusion criterion in 3 clinical trials for acute leukemia, of which 1 is open and 2 are closed.
`
`Of the trials that contain KIT Mutation and acute leukemia as inclusion criteria, 1 is phase 1 (0 open), 1 is phase
`
`2 (1 open), and 1 is no phase specified (0 open) [ 5 ].
`
`Therapy-Related Myelodysplastic Syndrome
`
`-
`
`KIT is altered in 1.41% of therapy-related myelodysplastic syndrome patients with KIT Mutation present in
`
`1.41% of all therapy-related myelodysplastic syndrome patients [ 4 ].
`
`KIT Mutation is an inclusion criterion in 3 clinical trials for therapy-related myelodysplastic syndrome, of which 3
`
`are open and 0 are closed. Of the trials that contain KIT Mutation and therapy-related myelodysplastic
`
`syndrome as inclusion criteria, 2 are phase 1 (2 open) and 1 is phase 2 (1 open) [ 5 ].
`
`Lymphoma
`
`KIT is altered in 1.15% of lymphoma patients with KIT Mutation present in 1.01% of all lymphoma patients [ 4 ].
`
`KIT Mutation is an inclusion criterion in 3 clinical trials for lymphoma, of which 2 are open and 1 is closed. Of
`
`the trials that contain KIT Mutation and lymphoma as inclusion criteria, 1 is phase 1 (0 open), 1 is phase
`
`1/phase 2 (1 open), and 1 is phase 2 (1 open) [ 5 ].
`
`Pancreatic Carcinoma
`
`KIT is altered in 0.62% of pancreatic carcinoma patients with KIT Mutation present in 0.62% of all pancreatic
`
`carcinoma patients [ 4 ].
`
`KIT Mutation is an inclusion criterion in 3 clinical trials for pancreatic carcinoma, of which 2 are open and 1 is
`
`closed. Of the trials that contain KIT Mutation and pancreatic carcinoma as inclusion criteria, 1 is phase 1 (0
`
`open) and 2 are phase 2 (2 open) [ 5 ].
`
`Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma
`
`-
`
`-
`
`-
`
`KIT is altered in 0.51% of chronic lymphocytic leukemia/small lymphocytic lymphoma patients with KIT Mutation
`
`present in 0.51% of all chronic lymphocytic leukemia/small lymphocytic lymphoma patients [ 4 ].
`
`KIT Mutation is an inclusion criterion in 3 clinical trials for chronic lymphocytic leukemia/small lymphocytic
`
`lymphoma, of which 2 are open and 1 is closed. Of the trials that contain KIT Mutation and chronic lymphocytic
`
`leukemia/small lymphocytic lymphoma as inclusion criteria, 1 is phase 1 (1 open), 1 is phase 2 (1 open), and 1
`
`is no phase specified (0 open) [ 5 ].
`
`Double-Hit Lymphoma
`
`KIT Mutation is an inclusion criterion in 3 clinical trials for double-hit lymphoma, of which 1 is open and 2 are
`
`closed. Of the trials that contain KIT Mutation and double-hit lymphoma as inclusion criteria, 3 are phase 1 (1
`
`open) [ 5 ].
`
`Refractory Anemia With Excess Blasts
`
`KIT Mutation is an inclusion criterion in 3 clinical trials for refractory anemia with excess blasts, of which 1 is
`
`open and 2 are closed. Of the trials that contain KIT Mutation and refractory anemia with excess blasts as
`
`inclusion criteria, 1 is phase 1 (0 open) and 2 are phase 2 (1 open) [ 5 ].
`
`Small Lymphocytic Lymphoma
`
`-
`
`-
`
`-
`
`KIT Mutation is an inclusion criterion in 3 clinical trials for small lymphocytic lymphoma, of which 1 is open and
`
`2 are closed. Of the trials that contain KIT Mutation and small lymphocytic lymphoma as inclusion criteria, 3 are
`
`phase 1 (1 open) [ 5 ].
`
`Soft Tissue Sarcoma
`
`KIT is altered in 30.77% of soft tissue sarcoma patients with KIT Mutation present in 28.89% of all soft tissue
`
`sarcoma patients [ 4 ].
`
`KIT Mutation is an inclusion criterion in 2 clinical trials for soft tissue sarcoma, of which 2 are open and 0 are
`
`closed. Of the trials that contain KIT Mutation and soft tissue sarcoma as inclusion criteria, 1 is phase 1 (1
`
`open) and 1 is phase 2 (1 open) [ 5 ].
`
`Mucosal Melanoma
`
`KIT is altered in 18.02% of mucosal melanoma patients with KIT Mutation present in 13.37% of all mucosal
`
`melanoma patients [ 4 ].
`
`KIT Mutation is an inclusion criterion in 2 clinical trials for mucosal melanoma, of which 1 is open and 1 is
`
`closed. Of the trials that contain KIT Mutation and mucosal melanoma as inclusion criteria, 2 are phase 2 (1
`
`open) [ 5 ].
`
`Anaplastic Large Cell Lymphoma
`
`-
`
`-
`
`-
`
`KIT is altered in 2.86% of anaplastic large cell lymphoma patients with KIT Mutation present in 2.86% of all
`
`anaplastic large cell lymphoma patients [ 4 ].
`
`KIT Mutation is an inclusion criterion in 2 clinical trials for anaplastic large cell lymphoma, of which 1 is open
`
`and 1 is closed. Of the trials that contain KIT Mutation and anaplastic large cell lymphoma as inclusion criteria,
`
`1 is phase 2 (1 open) and 1 is no phase specified (0 open) [ 5 ].
`
`Rigel Exhibit 1054
`Page 4 of 12
`
`

`

`Cancer
`
`-
`
`KIT is altered in 2.98% of cancer patients with KIT Mutation present in 2.51% of all cancer patients [ 4 ].
`
`KIT Mutation is an inclusion criterion in 2 clinical trials for cancer, of which 1 is open and 1 is closed. Of the
`
`trials that contain KIT Mutation and cancer as inclusion criteria, 1 is early phase 1 (0 open) and 1 is phase 2 (1
`
`open) [ 5 ].
`
`Colorectal Carcinoma
`
`KIT is altered in 2.04% of colorectal carcinoma patients with KIT Mutation present in 1.95% of all colorectal
`
`carcinoma patients [ 4 ].
`
`KIT Mutation is an inclusion criterion in 2 clinical trials for colorectal carcinoma, of which 1 is open and 1 is
`
`closed. Of the trials that contain KIT Mutation and colorectal carcinoma as inclusion criteria, 1 is phase 1 (0
`
`open) and 1 is phase 2 (1 open) [ 5 ].
`
`Bladder Carcinoma
`
`-
`
`-
`
`KIT is altered in 1.85% of bladder carcinoma patients with KIT Mutation present in 1.85% of all bladder
`
`carcinoma patients [ 4 ].
`
`KIT Mutation is an inclusion criterion in 2 clinical trials for bladder carcinoma, of which 1 is open and 1 is closed.
`
`Of the trials that contain KIT Mutation and bladder carcinoma as inclusion criteria, 1 is phase 1 (0 open) and 1
`
`is phase 2 (1 open) [ 5 ].
`
`Head And Neck Squamous Cell Carcinoma
`
`-
`
`KIT is altered in 1.89% of head and neck squamous cell carcinoma patients with KIT Mutation present in 1.65%
`
`of all head and neck squamous cell carcinoma patients [ 4 ].
`
`KIT Mutation is an inclusion criterion in 2 clinical trials for head and neck squamous cell carcinoma, of which 2
`
`are open and 0 are closed. Of the trials that contain KIT Mutation and head and neck squamous cell carcinoma
`
`as inclusion criteria, 1 is phase 1 (1 open) and 1 is phase 2 (1 open) [ 5 ].
`
`Ovarian Carcinoma
`
`-
`
`KIT is altered in 1.69% of ovarian carcinoma patients with KIT Mutation present in 1.54% of all ovarian
`
`carcinoma patients [ 4 ].
`
`KIT Mutation is an inclusion criterion in 2 clinical trials for ovarian carcinoma, of which 1 is open and 1 is closed.
`
`Of the trials that contain KIT Mutation and ovarian carcinoma as inclusion criteria, 1 is phase 1 (0 open) and 1
`
`is phase 2 (1 open) [ 5 ].
`
`Adenocarcinoma Of The Gastroesophageal Junction
`
`-
`
`KIT is altered in 1.41% of adenocarcinoma of the gastroesophageal junction patients with KIT Mutation present
`
`in 1.41% of all adenocarcinoma of the gastroesophageal junction patients [ 4 ].
`
`KIT Mutation is an inclusion criterion in 2 clinical trials for adenocarcinoma of the gastroesophageal junction, of
`
`which 2 are open and 0 are closed. Of the trials that contain KIT Mutation and adenocarcinoma of the
`
`gastroesophageal junction as inclusion criteria, 2 are phase 2 (2 open) [ 5 ].
`
`Head And Neck Carcinoma
`
`-
`
`KIT is altered in 2.11% of head and neck carcinoma patients with KIT Mutation present in 1.41% of all head and
`
`neck carcinoma patients [ 4 ].
`
`KIT Mutation is an inclusion criterion in 2 clinical trials for head and neck carcinoma, of which 1 is open and 1 is
`
`closed. Of the trials that contain KIT Mutation and head and neck carcinoma as inclusion criteria, 1 is phase 1
`
`(0 open) and 1 is phase 2 (1 open) [ 5 ].
`
`Breast Carcinoma
`
`-
`
`KIT is altered in 1.47% of breast carcinoma patients with KIT Mutation present in 1.07% of all breast carcinoma
`
`patients [ 4 ].
`
`KIT Mutation is an inclusion criterion in 2 clinical trials for breast carcinoma, of which 1 is open and 1 is closed.
`
`Of the trials that contain KIT Mutation and breast carcinoma as inclusion criteria, 1 is phase 1 (0 open) and 1 is
`
`phase 2 (1 open) [ 5 ].
`
`B-Cell Non-Hodgkin Lymphoma
`
`-
`
`KIT is altered in 1.03% of B-cell non-hodgkin lymphoma patients with KIT Mutation present in 0.94% of all B-cell
`
`non-hodgkin lymphoma patients [ 4 ].
`
`KIT Mutation is an inclusion criterion in 2 clinical trials for B-cell non-hodgkin lymphoma, of which 1 is open and
`
`1 is closed. Of the trials that contain KIT Mutation and B-cell non-hodgkin lymphoma as inclusion criteria, 1 is
`
`phase 1 (0 open) and 1 is phase 2 (1 open) [ 5 ].
`
`Follicular Lymphoma
`
`-
`
`KIT is altered in 0.92% of follicular lymphoma patients with KIT Mutation present in 0.92% of all follicular
`
`lymphoma patients [ 4 ].
`
`KIT Mutation is an inclusion criterion in 2 clinical trials for follicular lymphoma, of which 1 is open and 1 is
`
`closed. Of the trials that contain KIT Mutation and follicular lymphoma as inclusion criteria, 1 is phase 2 (1
`
`open) and 1 is no phase specified (0 open) [ 5 ].
`
`Rigel Exhibit 1054
`Page 5 of 12
`
`

`

`Myelofibrosis
`
`-
`
`KIT is altered in 0.6% of myelofibrosis patients with KIT Mutation present in 0.6% of all myelofibrosis patients
`
`[ 4 ].
`
`KIT Mutation is an inclusion criterion in 2 clinical trials for myelofibrosis, of which 1 is open and 1 is closed. Of
`
`the trials that contain KIT Mutation and myelofibrosis as inclusion criteria, 1 is phase 1 (0 open) and 1 is phase
`
`2 (1 open) [ 5 ].
`
`Mantle Cell Lymphoma
`
`KIT is altered in 0.56% of mantle cell lymphoma patients with KIT Mutation present in 0.56% of all mantle cell
`
`lymphoma patients [ 4 ].
`
`KIT Mutation is an inclusion criterion in 2 clinical trials for mantle cell lymphoma, of which 1 is open and 1 is
`
`closed. Of the trials that contain KIT Mutation and mantle cell lymphoma as inclusion criteria, 1 is phase 2 (1
`
`open) and 1 is no phase specified (0 open) [ 5 ].
`
`Burkitt Lymphoma
`
`-
`
`-
`
`KIT Mutation is an inclusion criterion in 2 clinical trials for Burkitt lymphoma, of which 1 is open and 1 is closed.
`
`Of the trials that contain KIT Mutation and Burkitt lymphoma as inclusion criteria, 1 is phase 2 (1 open) and 1 is
`
`no phase specified (0 open) [ 5 ].
`
`Lymphoblastic Lymphoma
`
`-
`
`KIT Mutation is an inclusion criterion in 2 clinical trials for lymphoblastic lymphoma, of which 2 are open and 0
`
`are closed. Of the trials that contain KIT Mutation and lymphoblastic lymphoma as inclusion criteria, 1 is phase
`
`1 (1 open) and 1 is phase 2 (1 open) [ 5 ].
`
`Lymphoplasmacytic Lymphoma
`
`-
`
`KIT Mutation is an inclusion criterion in 2 clinical trials for lymphoplasmacytic lymphoma, of which 1 is open and
`
`1 is closed. Of the trials that contain KIT Mutation and lymphoplasmacytic lymphoma as inclusion criteria, 1 is
`
`phase 2 (1 open) and 1 is no phase specified (0 open) [ 5 ].
`
`Marginal Zone Lymphoma
`
`-
`
`KIT Mutation is an inclusion criterion in 2 clinical trials for marginal zone lymphoma, of which 1 is open and 1 is
`
`closed. Of the trials that contain KIT Mutation and marginal zone lymphoma as inclusion criteria, 1 is phase 2 (1
`
`open) and 1 is no phase specified (0 open) [ 5 ].
`
`Myelodysplastic Syndrome With Excess Blasts-2
`
`KIT Mutation is an inclusion criterion in 2 clinical trials for myelodysplastic syndrome with excess blasts-2, of
`
`which 1 is open and 1 is closed. Of the trials that contain KIT Mutation and myelodysplastic syndrome with
`
`excess blasts-2 as inclusion criteria, 2 are phase 2 (1 open) [ 5 ].
`
`Prolymphocytic Leukemia
`
`-
`
`-
`
`KIT Mutation is an inclusion criterion in 2 clinical trials for prolymphocytic leukemia, of which 1 is open and 1 is
`
`closed. Of the trials that contain KIT Mutation and prolymphocytic leukemia as inclusion criteria, 1 is phase 2 (1
`
`open) and 1 is no phase specified (0 open) [ 5 ].
`
`Secondary Acute Myeloid Leukemia
`
`KIT Mutation is an inclusion criterion in 2 clinical trials for secondary acute myeloid leukemia, of which 2 are
`
`open and 0 are closed. Of the trials that contain KIT Mutation and secondary acute myeloid leukemia as
`
`inclusion criteria, 2 are phase 1 (2 open) [ 5 ].
`
`Systemic Mastocytosis With An Associated Hematological Neoplasm (SM-AHN)
`
`-
`
`-
`
`KIT is altered in 37.5% of systemic mastocytosis with an associated hematological neoplasm (SM-AHN)
`
`patients with KIT Mutation present in 37.5% of all systemic mastocytosis with an associated hematological
`
`neoplasm (SM-AHN) patients [ 4 ].
`
`KIT Mutation is an inclusion criterion in 1 clinical trial for systemic mastocytosis with an associated
`
`hematological neoplasm (SM-AHN), of which 1 is open and 0 are closed. Of the trial that contains KIT Mutation
`
`and systemic mastocytosis with an associated hematological neoplasm (SM-AHN) as inclusion criteria, 1 is
`
`phase 1 (1 open) [ 5 ].
`
`Systemic Mastocytosis
`
`-
`
`KIT is altered in 35.29% of systemic mastocytosis patients with KIT Mutation present in 35.29% of all systemic
`
`mastocytosis patients [ 4 ].
`
`KIT Mutation is an inclusion criterion in 1 clinical trial for systemic mastocytosis, of which 1 is open and 0 are
`
`closed. Of the trial that contains KIT Mutation and systemic mastocytosis as inclusion criteria, 1 is phase 1 (1
`
`open) [ 5 ].
`
`Sarcoma
`
`-
`
`KIT is altered in 16.82% of sarcoma patients with KIT Mutation present in 15.18% of all sarcoma patients [ 4 ].
`
`Rigel Exhibit 1054
`Page 6 of 12
`
`

`

`KIT Mutation is an inclusion criterion in 1 clinical trial for sarcoma, of which 0 are open and 1 is closed. Of the
`
`trial that contains KIT Mutation and sarcoma as inclusion criteria, 1 is phase 1 (0 open) [ 5 ].
`
`Acral Lentiginous Melanoma
`
`-
`
`KIT is altered in 11.89% of acral lentiginous melanoma patients with KIT Mutation present in 9.09% of all acral
`
`lentiginous melanoma patients [ 4 ].
`
`KIT Mutation is an inclusion criterion in 1 clinical trial for acral lentiginous melanoma, of which 0 are open and 1
`
`is closed. Of the trial that contains KIT Mutation and acral lentiginous melanoma as inclusion criteria, 1 is phase
`
`2 (0 open) [ 5 ].
`
`Malignant Germ Cell Tumor
`
`-
`
`KIT is altered in 9.28% of malignant germ cell tumor patients with KIT Mutation present in 8.68% of all
`
`malignant germ cell tumor patients [ 4 ].
`
`KIT Mutation is an inclusion criterion in 1 clinical trial for malignant germ cell tumor, of which 1 is open and 0 are
`
`closed. Of the trial that contains KIT Mutation and malignant germ cell tumor as inclusion criteria, 1 is phase 1
`
`(1 open) [ 5 ].
`
`Thymic Carcinoma
`
`-
`
`KIT is altered in 6.25% of thymic carcinoma patients with KIT Mutation present in 6.25% of all thymic carcinoma
`
`patients [ 4 ].
`
`KIT Mutation is an inclusion criterion in 1 clinical trial for thymic carcinoma, of which 1 is open and 0 are closed.
`
`Of the trial that contains KIT Mutation and thymic carcinoma as inclusion criteria, 1 is phase 2 (1 open) [ 5 ].
`
`Nasal Cavity And Paranasal Sinus Carcinoma
`
`-
`
`KIT is altered in 4.35% of nasal cavity and paranasal sinus carcinoma patients with KIT Mutation present in
`
`4.35% of all nasal cavity and paranasal sinus carcinoma patients [ 4 ].
`
`KIT Mutation is an inclusion criterion in 1 clinical trial for nasal cavity and paranasal sinus carcinoma, of which 1
`
`is open and 0 are closed. Of the trial that contains KIT Mutation and nasal cavity and paranasal sinus
`
`carcinoma as inclusion criteria, 1 is phase 2 (1 open) [ 5 ].
`
`Penile Carcinoma
`
`-
`
`KIT is altered in 3.57% of penile carcinoma patients with KIT Mutation present in 3.57% of all penile carcinoma
`
`patients [ 4 ].
`
`KIT Mutation is an inclusion criterion in 1 clinical trial for penile carcinoma, of which 1 is open and 0 are closed.
`
`Of the trial that contains KIT Mutation and penile carcinoma as inclusion criteria, 1 is phase 1 (1 open) [ 5 ].
`
`Malignant Uterine Neoplasm
`
`KIT is altered in 3.43% of malignant uterine neoplasm patients with KIT Mutation present in 3.29% of all
`
`malignant uterine neoplasm patients [ 4 ].
`
`KIT Mutation is an inclusion criterion in 1 clinical trial for malignant uterine neoplasm, of which 1 is open and 0
`
`are closed. Of the trial that contains KIT Mutation and malignant uterine neoplasm as inclusion criteria, 1 is
`
`phase 2 (1 open) [ 5 ].
`
`Small Cell Lung Carcinoma
`
`-
`
`-
`
`KIT is altered in 4.92% of small cell lung carcinoma patients with KIT Mutation present in 2.65% of all small cell
`
`lung carcinoma patients [ 4 ].
`
`KIT Mutation is an inclusion criterion in 1 clinical trial for small cell lung carcinoma, of which 1 is open and 0 are
`
`closed. Of the trial that contains KIT Mutation and small cell lung carcinoma as inclusion criteria, 1 is phase 2 (1
`
`open) [ 5 ].
`
`Malignant Laryngeal Neoplasm
`
`-
`
`KIT is altered in 2.35% of malignant laryngeal neoplasm patients with KIT Mutation present in 2.35% of all
`
`malignant laryngeal neoplasm patients [ 4 ].
`
`KIT Mutation is an inclusion criterion in 1 clinical trial for malignant laryngeal neoplasm, of which 1 is open and
`
`0 are closed. Of the trial that contains KIT Mutation and malignant laryngeal neoplasm as inclusion criteria, 1 is
`
`phase 2 (1 open) [ 5 ].
`
`Urothelial Carcinoma
`
`KIT is altered in 2.15% of urothelial carcinoma patients with KIT Mutation present in 2.05% of all urothelial
`
`carcinoma patients [ 4 ].
`
`KIT Mutation is an inclusion criterion in 1 clinical trial for urothelial carcinoma, of which 1 is open and 0 are
`
`closed. Of the trial that contains KIT Mutation and urothelial carcinoma as inclusion criteria, 1 is phase 2 (1
`
`open) [ 5 ].
`
`Leukemia
`
`KIT is altered in 1.95% of leukemia patients with KIT Mutation present in 1.92% of all leukemia patients [ 4 ].
`
`KIT Mutation is an inclusion criterion in 1 clinical trial for leukemia, of which 1 is open and 0 are closed. Of the
`
`trial that contains KIT Mutation and leukemia as inclusion criteria, 1 is phase 1/phase 2 (1 open) [ 5 ].
`
`-
`
`-
`
`Rigel Exhibit 1054
`Page 7 of 12
`
`

`

`Glioblastoma
`
`-
`
`KIT is altered in 5.93% of glioblastoma patients with KIT Mutation present in 1.88% of all glioblastoma patients
`
`[ 4 ].
`
`KIT Mutation is an inclusion criterion in 1 clinical trial for glioblastoma, of which 0 are open and 1 is closed. Of
`
`the trial that contains KIT Mutation and glioblastoma as inclusion criteria, 1 is phase 1 (0 open) [ 5 ].
`
`Malignant Glioma
`
`-
`
`KIT is altered in 5.59% of malignant glioma patients with KIT Mutation present in 1.85% of all malignant glioma
`
`patients [ 4 ].
`
`KIT Mutation is an inclusion criterion in 1 clinical trial for malignant glioma, of which 1 is open and 0 are closed.
`
`Of the trial that contains KIT Mutation and malignant glioma as inclusion criteria, 1 is phase 1 (1 open) [ 5 ].
`
`Oropharyngeal Carcinoma
`
`-
`
`KIT is altered in 1.84% of oropharyngeal carcinoma patients with KIT Mutation present in 1.84% of all
`
`oropharyngeal carcinoma patients [ 4 ].
`
`KIT Mutation is an inclusion criterion in 1 clinical trial for oropharyngeal carcinoma, of which 1 is open and 0 are
`
`closed. Of the trial that contains KIT Mutation and oropharyngeal carcinoma as inclusion criteria, 1 is phase 2 (1
`
`open) [ 5 ].
`
`Oropharyngeal Squamous Cell Carcinoma
`
`-
`
`KIT is altered in 1.84% of oropharyngeal squamous cell carcinoma patients with KIT Mutation present in 1.84%
`
`of all oropharyngeal squamous cell carcinoma patients [ 4 ].
`
`KIT Mutation is an inclusion criterion in 1 clinical trial for oropharyngeal squamous cell carcinoma, of which 1 is
`
`open and 0 are closed. Of the trial that contains KIT Mutation and oropharyngeal squamous cell carcinoma as
`
`inclusion criteria, 1 is phase 1 (1 open) [ 5 ].
`
`Gallbladder Carcinoma
`
`KIT is altered in 1.81% of gallbladder carcinoma patients with KIT Mutation present in 1.81% of all gallbladder
`
`carcinoma patients [ 4 ].
`
`KIT Mutation is an inclusion criterion in 1 clinical trial for gallbladder carcinoma, of which 1 is open and 0 are
`
`closed. Of the trial that contains KIT Mutation and gallbladder carcinoma as inclusion criteria, 1 is phase 2 (1
`
`open) [ 5 ].
`
`Lung Carcinoma
`
`KIT is altered in 2.19% of lung carcinoma patients with KIT Mutation present in 1.79% of all lung carcinoma
`
`patients [ 4 ].
`
`KIT Mutation is an inclusion criterion in 1 clinical trial for lung carcinoma, of which 1 is open and 0 are closed.
`
`Of the trial that contains KIT Mutation and lung carcinoma as inclusion criteria, 1 is phase 2 (1 open) [ 5 ].
`
`T-Cell And NK-Cell Neoplasm
`
`-
`
`-
`
`-
`
`KIT is altered in 1.79% of T-cell and NK-cell neoplasm patients with KIT Mutation present in 1.59% of all T-cell
`
`and NK-cell neoplasm patients [ 4 ].
`
`KIT Mutation is an inclusion criterion in 1 clinical trial for T-cell and NK-cell neoplasm, of which 1 is open and 0
`
`are closed. Of the trial that contains KIT Mutation and T-cell and NK-cell neoplasm as inclusion criteria, 1 is
`
`phase 2 (1 open) [ 5 ].
`
`Cervical Carcinoma
`
`-
`
`KIT is altered in 1.55% of cervical carcinoma patients with KIT Mutation present in 1.55% of all cervical
`
`carcinoma patients [ 4 ].
`
`KIT Mutation is an inclusion criterion in 1 clinical trial for cervical carcinoma, of which 1 is open and 0 are
`
`closed. Of the trial that contains KIT Mutation and cervical carcinoma as inclusion criteria, 1 is phase 2 (1 open)
`
`[ 5 ].
`
`Nasopharyngeal Carcinoma
`
`KIT is altered in 4.11% of nasopharyngeal carcinoma patients with KIT Mutation present in 1.37% of all
`
`nasopharyngeal carcinoma patients [ 4 ].
`
`KIT Mutation is an inclusion criterion in 1 clinical trial for nasopharyngeal carcinoma, of which 1 is open and 0
`
`are closed. Of the trial that contains KIT Mutation and nasopharyngeal carcinoma as inclusion criteria, 1 is
`
`phase 2 (1 open) [ 5 ].
`
`Diffuse Large B-Cell Lymphoma
`
`-
`
`-
`
`KIT is altered in 1.51% of diffuse large B-cell lymphoma patients with KIT Mutation present in 1.32% of all
`
`diffuse large B-cell lymphoma patients [ 4 ].
`
`KIT Mutation is an inclusion criterion in 1 clinical trial for diffuse large B-cell lymphoma, of which 0 are open and
`
`1 is closed. Of the trial that contains KIT Mutation and diffuse large B-cell lymphoma as inclusion criteria, 1 is
`
`phase 1 (0 open) [ 5 ].
`
`Rigel Exhibit 1054
`Page 8 of 12
`
`

`

`Anaplastic Astrocytoma
`
`KIT is altered in 4.74% of anaplastic astrocytoma patients with KIT Mutation present in 1.29% of all anaplastic
`
`astrocytoma patients [ 4 ].
`
`KIT Mutation is an inclusion criterion in 1 clinical trial for anaplastic astrocytoma, of which 0 are open and 1 is
`
`closed. Of the trial that contains KIT Mutation and anaplastic astrocytoma as inclusion criteria, 1 is phase 1 (0
`
`open) [ 5 ].
`
`Hepatobiliary Neoplasm
`
`KIT is alt